Remote Electrical Neuromodulation as First-Line Treatment for Acute Migraine Relief Shows Promise

Physica System Trabecular Titanium Tibial Plate – 1st Surgery Performed by Dr. Ivan De Martino

Luigi Ferrari, LimaCorporate CEO, commented: "TT Tibial plate is an important addition to the Physica system and will enable LimaCorporate to approach a new segment of the total knee market. 

Virtual Short Course Offers New Insights for Corrosion Prevention and Sustainability of Biomedical Implants and Devices

AMPP’s Corrosion Technical Series is now offering a new 6-hour short course on corrosion prevention in metallic biomaterials and biomedical devices.

Dr. Michael Cantor Named Intuition Robotics 1st Chief Medical Officer

The company recently announced its plan to extend to healthcare.

The American Headache Society published an article in its peer-reviewed journal, Headache: The Journal of Head and Face Pain, highlighting the promise of Remote Electrical Neuromodulation (REN) as an alternative to current treatment options and as a potential first-line therapy for acute migraine relief.

“While migraine is one of the most prevalent and disabling neurological diseases affecting a significant portion of the global population, many are still looking for an effective, long-term treatment option,” said Alan Rapoport, M.D. author of the article and Professor of Neurology at UCLA. “For the first time, REN offers an effective, safe and non-invasive alternative for acute migraine treatment and may be suitable as first-line therapy for some users.”

The article Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine, reviews a pilot study and a pivotal study conducted to determine the safety and efficacy of the Nerivio™, Theranica’s smartphone-connected prescription migraine wearable device. Both studies showed positive results, demonstrating REN is as effective a treatment for acute treatment of migraine as standard pharmacological treatments, with a favorable safety profile.

The Nerivio alleviates migraine symptoms by stimulating the body’s Conditioned Pain Modulation (CPM) response, in which one painful stimuli modulates pain in other regions of the body. As a smartphone-connected wearable, users can individually control the strength of their therapy and easily share data collected with healthcare providers to improve treatment plans. The Nerivio is the first device to use REN to stimulate CPM by placing the device on the upper arm at the onset of a migraine episode.

“The future of migraine care lies in non-invasive, drug-free technologies that are effective and affordable,” said Alon Ironi, CEO and co-founder of Theranica. “For those living with migraine, the search for long-term symptom relief is not easy. REN opens the door for new therapeutic alternatives, with Nerivio leading the way.”

The article will be published in Headache’s print journal in the coming weeks.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles